Merus (NASDAQ:MRUS) PT Raised to $93.00

Merus (NASDAQ:MRUS) had its price target lifted by Citigroup from $70.00 to $93.00 in a report released on Wednesday morning, Benzinga reports. Citigroup currently has a buy rating on the biotechnology company’s stock.

A number of other analysts also recently weighed in on the company. William Blair reiterated an outperform rating on shares of Merus in a research report on Monday, April 22nd. Needham & Company LLC reiterated a buy rating and set a $66.00 price target on shares of Merus in a report on Friday, May 24th. Stifel Nicolaus lifted their target price on shares of Merus from $90.00 to $99.00 and gave the stock a buy rating in a research report on Monday, June 17th. BMO Capital Markets increased their price target on Merus from $84.00 to $91.00 and gave the company an outperform rating in a research note on Tuesday, June 4th. Finally, HC Wainwright reissued a buy rating and set a $65.00 target price on shares of Merus in a research note on Friday, May 24th. One research analyst has rated the stock with a sell rating and twelve have given a buy rating to the company. Based on data from MarketBeat, Merus presently has an average rating of Moderate Buy and an average price target of $80.90.

Merus Trading Down 1.7 %

MRUS opened at $59.17 on Wednesday. The stock has a market cap of $3.47 billion, a PE ratio of -21.36 and a beta of 1.10. The stock’s fifty day simple moving average is $50.49 and its 200 day simple moving average is $42.77. Merus has a 1-year low of $19.81 and a 1-year high of $61.61.

Merus (NASDAQ:MRUS) last announced its earnings results on Wednesday, May 8th. The biotechnology company reported ($0.59) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.24. The company had revenue of $7.89 million for the quarter, compared to analyst estimates of $8.94 million. Merus had a negative return on equity of 44.13% and a negative net margin of 390.36%. Equities analysts forecast that Merus will post -3.1 earnings per share for the current year.

Insider Buying and Selling at Merus

In other news, VP Harry Shuman sold 1,000 shares of the firm’s stock in a transaction that occurred on Monday, June 10th. The stock was sold at an average price of $53.22, for a total value of $53,220.00. Following the transaction, the vice president now owns 7,002 shares in the company, valued at $372,646.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Merus news, VP Harry Shuman sold 1,000 shares of the company’s stock in a transaction dated Monday, June 10th. The shares were sold at an average price of $53.22, for a total value of $53,220.00. Following the completion of the sale, the vice president now directly owns 7,002 shares of the company’s stock, valued at approximately $372,646.44. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Peter B. Silverman sold 10,000 shares of Merus stock in a transaction that occurred on Thursday, June 27th. The stock was sold at an average price of $60.00, for a total transaction of $600,000.00. The disclosure for this sale can be found here. In the last 90 days, insiders sold 24,300 shares of company stock worth $1,392,792. 4.57% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Quadrant Capital Group LLC boosted its holdings in shares of Merus by 37.7% in the 4th quarter. Quadrant Capital Group LLC now owns 1,253 shares of the biotechnology company’s stock worth $34,000 after buying an additional 343 shares during the last quarter. Tower Research Capital LLC TRC boosted its stake in Merus by 64.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 2,120 shares of the biotechnology company’s stock valued at $58,000 after acquiring an additional 828 shares during the last quarter. California State Teachers Retirement System grew its position in shares of Merus by 2.9% during the 1st quarter. California State Teachers Retirement System now owns 33,745 shares of the biotechnology company’s stock valued at $1,520,000 after acquiring an additional 936 shares during the period. Swiss National Bank grew its position in shares of Merus by 1.9% during the 1st quarter. Swiss National Bank now owns 74,054 shares of the biotechnology company’s stock valued at $3,335,000 after acquiring an additional 1,400 shares during the period. Finally, Exchange Traded Concepts LLC increased its stake in shares of Merus by 34.0% during the 4th quarter. Exchange Traded Concepts LLC now owns 5,753 shares of the biotechnology company’s stock worth $158,000 after purchasing an additional 1,459 shares during the last quarter. Institutional investors own 96.14% of the company’s stock.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.